araag2/HINT huggingface dataset:
Clinical trial NCT02496078 (phase 3, status: completed)
Conditions: hepatitis c
ICD codes: B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, B15.9
Drugs: daclatasvir, asunaprevir
SMILES: COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(N1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CN=C(N1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C, COC1=CN=C(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)C2=C1C=CC(Cl)=C2
Eligibility criteria:

        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Patients chronically infected with HCV Genotype 1b

          -  No previous exposure to any interferon formulation, Ribavirin (RBV), and HCV direct
             acting antiviral agent

          -  HCV RNA viral load ≥ 10,000 IU/mL at screening

          -  Seronegative for HIV and HBsAg

          -  BMI of 18-35 kg/m2, inclusive

          -  Patients with compensated cirrhosis are permitted

        Exclusion Criteria:

          -  Infection with HCV other than genotype (GT) -1b

          -  Evidence of decompensated liver disease including, but not limited to, a history or
             presence of ascites, bleeding varices, or hepatic encephalopathy

          -  Evidence of a medical condition contributing to chronic liver disease other than HCV

          -  Diagnosed or suspected hepatocellular carcinoma or other malignancies

          -  Uncontrolled diabetes or hypertension

          -  History of moderate to severe depression. Well-controlled mild depression is allowed

          -  Confirmed alanine aminotransferase (ALT) ≥ 5x Upper Limit of Normal (ULN)

          -  Confirmed platelet count < 50,000 cells/mm3

          -  Confirmed hemoglobin < 8.5 g/dL
Clinical trial NCT02500706 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 1
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: faster-acting insulin aspart, insulin aspart, insulin degludec
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria: - Male or female, age greater than or equal to 18 years ( for Japan and
        Taiwan: age greater than or equal to 20 years) at the time of signing informed consent -
        Type 1 Diabetes Mellitus (based on clinical judgement and/or supported by laboratory
        analysis as per local guidelines) 12 months or more prior to screening - Currently treated
        with a basal-bolus insulin regimen for at least 12 months prior to screening (Visit 1) -
        Currently treated with a basal insulin analogue for at least 4 months prior to screening
        (Visit 1) - HbA1c 7.0-9.5% (53-80 mmol/mol) (both inclusive) as assessed by central
        laboratory - Body Mass Index less than or equal to 35.0 kg/m^2 Exclusion Criteria: - Within
        the past 180 days any of the following: myocardial infarction, stroke or hospitalization
        for unstable angina and/or transient ischemic attack - Subjects presently classified as
        being in New York Heart Association (NYHA) Class IV Currently planned coronary, carotid or
        peripheral artery revascularisation - Diabetic ketoacidosis requiring hospitalisation
        within the last 180 days prior to screening (Visit 1) - Treatment with any medication for
        the indication of diabetes or obesity other than stated in the inclusion criteria in a
        period of three months before screening (Visit 1)
Clinical trial NCT02501161 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 2
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: insulin degludec/liraglutide, insulin glargine
SMILES: CN(C)C(=N)NC(N)=N, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female, age greater than or equal to 18 years at the time of signing informed
             consent

          -  Subjects diagnosed with type 2 diabetes mellitus

          -  HbA1c 7.0-11.0% (both inclusive) (53-97 mmol/mol) by central laboratory analysis

          -  Body mass index greater than or equal to 20 kg/m^2

          -  Insulin naïve subjects; however short term insulin treatment for a maximum of 14 days
             prior to the day of screening is allowed, as is prior insulin treatment for
             gestational diabetes

          -  Stable daily dose(s) including any of the following antidiabetic drug(s)/regimens
             within 90 days prior to the day of screening: a) Biguanides (metformin greater than or
             equal to 1500 mg or maximum tolerated dose documented in the subject medical record),
             b) Other OAD(s) allowed: sulphonylurea, glinides, pioglitazone, and DPP4-inhibitors
             (greater than or equal to half of the maximum approved dose according to local label
             or maximum tolerated dose as documented in subjects medical record)

        Exclusion Criteria:

          -  Screening calcitonin greater than or equal to 50 ng/L

          -  Renal impairment estimated Glomerular Filtration Rate (eGFR) less than 60 ml/min/1.73
             m2 as per CKD-EPI value to be defined as listed in the classification CKD-EPI using
             IDMS for serum creatinine measurement on the day of screening

          -  Impaired liver function, defined as ALAT or ASAT greater than or equal to 2.5 times
             upper limit of normal

          -  Family or personal history of Multiple Endocrine Neoplasia Type 2 or Medullary Thyroid
             Carcinoma

          -  History of pancreatitis (acute or chronic)

          -  Treatment with any medication for the indication of diabetes or obesity other than
             stated in the inclusion criteria in a period of 90 days before the day of screening

          -  Anticipated initiation or change in concomitant medications for more than 14
             consecutive days or on a frequent basis known to affect weight or glucose metabolism
             (e.g. orlistat, thyroid hormones, corticosteroids)
Clinical trial NCT02504008 (phase 3, status: unknown status)
Conditions: complex regional pain syndrome, reflex sympathetic dystrophy
ICD codes: H44.133, H44.131, H44.132, H44.139, S14.5XXS, S14.5XXA, S14.5XXD
Drugs: axs-02 (oral zoledronate), placebo
SMILES: OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Male or female of at least 18 years of age

          -  Recently confirmed diagnosis of CRPS-1 (Budapest criteria)

          -  Average pain intensity score of ≥ 5 (based on an 11-point scale [0 - 10])

          -  Willing and able to provide written informed consent

        Key Exclusion Criteria:

          -  Received chronic opioid therapy within 4 weeks

          -  Received a sympathetic nerve block within 3 weeks

          -  Active litigation or a pending workers' compensation decision

          -  Any other clinically significant medical or pain condition (eg, Parkinson's disease,
             cognitive impairment, or fibromyalgia) or clinical laboratory abnormality that would
             in the investigator's judgment interfere with the subject's ability to participate in
             the study
Clinical trial NCT02504099 (phase 3, status: terminated)
Conditions: chronic hepatitis c infection
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: ombitasvir/paritaprevir/ritonavir and dasabuvir, ombitasvir/paritaprevir/ritonavir, ribavirin
SMILES: CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1, [H][C@@]12C[C@]1(NC(=O)[C@]1([H])C[C@H](CN1C(=O)[C@H](CCCCC\C=C/2)NC(=O)C1=CN=C(C)C=N1)OC1=NC2=C(C=CC=C2)C2=C1C=CC=C2)C(=O)NS(=O)(=O)C1CC1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Reason stopped: 
    study stopped due to low enrollment
  
Eligibility criteria:

        Inclusion Criteria:

          1. Male or female, at least 18 years of age at time of screening

          2. Chronic hepatitis C virus (HCV) infection prior to study enrollment with screening
             laboratory results indicating HCV genotype 1 or 4 infection

          3. Early stage hepatocellular carcinoma (HCC) diagnosed based on the typical hallmark of
             HCC (hypervascular in the arterial phase with washout in the portal venous or delayed
             phases)

          4. Compensated cirrhosis defined as a Child-Pugh score of 5 or 6 at Screening

             • A minimal rim of ascites if detected at imaging is acceptable. Exclude ascites that
             requires the need to apply diuretic treatment to control ascites

          5. Documented complete response to HCC treatment.

          6. Females must be post-menopausal for more than 2 years or surgically sterile or
             practicing acceptable forms of birth control.

        Exclusion Criteria:

          1. Use of known strong or moderate inducers of cytochrome P450 3A (CYP3A) in participants
             receiving ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) with and without dasabuvir
             (DSV), strong inducers and inhibitors (e.g., gemfibrozil) of cytochrome P450 2C8
             (CYP2C8) in participants receiving OBV/PTV/r with DSV, medications contraindicated for
             ritonavir or RBV (for those that receive RBV) within 2 weeks or 10 half-lives (if
             known), whichever is longer, prior to study drug . For medications contraindicated
             with AbbVie's 2-direct-acting antiviral agent (2-DAA) and 3-DAA regimen, refer to the
             recommended prescribing information section of the approved local product labels.

          2. Positive test result for hepatitis B surface antigen (HBsAg) or anti-human
             immunodeficiency virus antibody (HIV Ab).

          3. Patients regardless of eligibility to liver transplant, who have a comorbid disease
             that might preclude completion of study follow-up.

          4. Clinically significant abnormalities, other than HCV infection, in a participant with
             HCC based upon the medical history, physical examination, vital signs, laboratory
             profile and a 12-lead electrocardiogram (ECG) that make the participant an unsuitable
             candidate for this study in the opinion of the investigator.
Clinical trial NCT02504268 (phase 3, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: abatacept, methotrexate
SMILES: [H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
Eligibility criteria:

        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Rheumatoid arthritis (RA) diagnosis less than 6 months

          -  CRP > 3 mg/L or Erythrocyte Sedimentation Rate (ESR) ≥ 28 mm/h

          -  At least 3 swollen and 3 tender joints

          -  Anti-citrullinated protein antibodies (ACPA) positive

        Exclusion Criteria:

          -  At risk for tuberculosis

          -  Have acute infection

          -  Have chronic or recurrent bacterial or serious latent viral infection

          -  History of malignancies in the last 5 years except squamous skin, basal skin or
             cervical carcinoma

          -  Previous treatment with any conventional or biologic Disease-modifying anti rheumatic
             drugs (DMARD)
Clinical trial NCT02512510 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease (copd)
ICD codes: G91.1, I42.1, N11.1, J05.0, G47.33, J44.9, N13.8
Drugs: td-4208, placebo
SMILES: CN(CCN1CCC(CC1)OC(=O)NC1=CC=CC=C1C1=CC=CC=C1)C(=O)C1=CC=C(CN2CCC(CC2)C(N)=O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subject is a male or female subject 40 years of age or older

        Exclusion Criteria:

          -  Females who are pregnant, lactating, breast-feeding or planning to become pregnant
             during the study
Clinical trial NCT02513550 (phase 3, status: completed)
Conditions: plaque psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: ixekizumab, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Present with chronic plaque psoriasis for at least 6 months prior to enrollment

          -  At least 10% BSA of psoriasis at screening and at enrollment

          -  sPGA score of at least 3 and PASI score of at least 12 at screening and at enrollment

          -  Candidates for phototherapy and/or systemic therapy

          -  Participant must agree to use reliable method of birth control during the study; women
             must continue using birth control for at least 12 weeks after stopping treatment

        Exclusion Criteria:

          -  Predominant pattern of pustular, erythrodermic, or guttate forms of psoriasis

          -  History of drug-induced psoriasis

          -  Cannot avoid excessive sun exposure or use of tanning booths for at least 4 weeks
             prior to enrollment and during the study

          -  Received systemic non-biologic psoriasis therapy or phototherapy within the previous 4
             weeks; or had topical psoriasis treatment within the previous 2 weeks prior to
             enrollment

          -  Concurrent or recent use of any biologic agent

          -  Have participated in any study with ixekizumab

          -  Received a live vaccination within 12 weeks prior to enrollment

          -  Serious disorder or illness other than psoriasis

          -  Ongoing or serious infection within the last 12 weeks or evidence of tuberculosis

          -  Major surgery within 8 weeks of baseline, or will require surgery during the study

          -  Breastfeeding or nursing (lactating) women
Clinical trial NCT02514473 (phase 3, status: completed)
Conditions: cystic fibrosis
ICD codes: E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, P09.4
Drugs: vx-809, placebo, vx-770
SMILES: CC1=CC=C(NC(=O)C2(CC2)C2=CC=C3OC(F)(F)OC3=C2)N=C1C1=CC(=CC=C1)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(C)(C)C1=CC(=C(O)C=C1NC(=O)C1=CNC2=CC=CC=C2C1=O)C(C)(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects who weigh ≥15 kg without shoes a the Screening Visit

          -  Subjects with confirmed diagnosis of CF at the Screening Visit.

          -  Subjects who are homozygous for the F508del CFTR mutation

          -  Subjects with ppFEV1 of ≥70 percentage points adjusted for age, sex, and height

          -  Subjects with a screening LCI2.5 result greater than or equal to 7.5

        Exclusion Criteria:

          -  History of any comorbidity reviewed at the Screening Visit that, in the opinion of the
             investigator, might confound the results of the study or pose an additional risk in
             administering study drug to the subject.

          -  Any clinically significant laboratory abnormalities at the Screening Visit that would
             interfere with the study assessments or pose an undue risk for the subject

          -  Clinically significant abnormalities in hemoglobin, liver function, or renal function
             at the Screening Visit.

          -  An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in
             therapy for pulmonary disease within 28 days before Day 1

          -  History of solid organ or hematological transplantation at the Screening Visit
Clinical trial NCT02514577 (phase 3, status: completed)
Conditions: plaque psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: idp-122 lotion, idp-122 vehicle lotion
SMILES: CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Key Inclusion Criteria:

          -  Male or female, of any race, at least 18 years of age (inclusive).

          -  Freely provides both verbal and written informed consent.

          -  Has an area of plaque psoriasis appropriate for topical treatment that covers a body
             surface area (BSA) of at least 3%, but no more than 12%. The face, scalp, palms,
             soles, axillae, and intertriginous areas are to be excluded in this calculation.

          -  Is willing and able to avoid prolonged exposure of the treatment area to ultraviolet
             radiation (natural and artificial) for the duration of the study.

          -  Has a clinical diagnosis of psoriasis at the Baseline visit with an IGA score of 3 or
             4 (the face, scalp, palms, soles, axillae, and intertriginous areas are to be excluded
             from this calculation, if psoriasis is present).

        Key Exclusion Criteria:

          -  Has spontaneously improving or rapidly deteriorating plaque psoriasis or pustular
             psoriasis, as determined by the Investigator.

          -  Presents with psoriasis that was treated with prescription medication and failed to
             respond to treatment, even partially or temporarily, as determined by the
             Investigator.

          -  Presents with any concurrent skin condition that could interfere with the evaluation
             of the treatment areas, as determined by the Investigator.

          -  Is pregnant, nursing an infant, or planning a pregnancy during the study period.

          -  Has received treatment with any investigational drug or device within 60 days or 5
             drug half-lives (whichever is longer) prior to the Baseline visit or is concurrently
             participating in another clinical study with an investigational drug or device.
Clinical trial NCT02515097 (phase 3, status: completed)
Conditions: plaque psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: idp-122 lotion, idp-122 vehicle lotion
SMILES: CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female, of any race, at least 18 years of age (inclusive).

          -  Freely provides both verbal and written informed consent.

          -  Has an area of plaque psoriasis appropriate for topical treatment that covers a body
             surface area (BSA) of at least 3%, but no more than 12%. The face, scalp, palms,
             soles, axillae, and intertriginous areas are to be excluded in this calculation.

          -  Is willing and able to avoid prolonged exposure of the treatment area to ultraviolet
             radiation (natural and artificial) for the duration of the study.

          -  Has a clinical diagnosis of psoriasis at the Baseline visit with an IGA score of 3 or
             4. (The face, scalp, palms, soles, axillae and intertriginous areas are to be excluded
             in this assessment).

        Exclusion Criteria:

          -  Has spontaneously improving or rapidly deteriorating plaque psoriasis or pustular
             psoriasis, as determined by the Investigator.

          -  Presents with psoriasis that was treated with prescription medication and failed to
             respond to treatment, even partially or temporarily, as determined by the
             Investigator.

          -  Presents with any concurrent skin condition that could interfere with the evaluation
             of the treatment areas, as determined by the Investigator.

          -  Is pregnant, nursing an infant, or planning a pregnancy during the study period.

          -  Has received treatment with any investigational drug or device within 60 days or 5
             drug half-lives (whichever is longer) prior to the Baseline visit or is concurrently
             participating in another clinical study with an investigational drug or device.
Clinical trial NCT02516410 (phase 3, status: completed)
Conditions: cystic fibrosis
ICD codes: E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, P09.4
Drugs: vx-661 plus ivacaftor combination, ivacaftor, placebo (matched to vx-661 plus ivacaftor combination), placebo (matched to ivacaftor)
SMILES: CC(C)(C)C1=CC(=C(O)C=C1NC(=O)C1=CNC2=CC=CC=C2C1=O)C(C)(C)C, CC(C)(C)C1=CC(=C(O)C=C1NC(=O)C1=CNC2=CC=CC=C2C1=O)C(C)(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Confirmed diagnosis of CF defined as a sweat chloride value greater than or equal to
             (>=)60 millimole per liter (mmol/L) by quantitative pilocarpine iontophoresis.

          -  Heterozygous for the F508del-CFTR mutation and with a second CFTR mutation that is not
             likely to respond to VX-661 and/or ivacaftor therapy, genotype to be confirmed via
             assessment at the Screening Visit.

          -  Forced Expiratory Volume in 1 Second (FEV1) >=40 percent (%) and less than or equal to
             (<=)90% of predicted normal for age, sex, and height at Screening Visit.

        Exclusion Criteria:

          -  History of any comorbidity that, in the opinion of the investigator, might confound
             the results of the study or pose an additional risk in administering study drug to the
             participant.

          -  An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in
             therapy (including antibiotics) for pulmonary disease within 28 days before Day 1
             (first dose of study drug).

          -  History of solid organ or hematological transplantation.

          -  Ongoing or prior participation in an investigational drug study or use of commercially
             available CFTR modulator within 30 days of screening.

          -  Pregnant or nursing females.
Clinical trial NCT02518139 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease (copd)
ICD codes: G91.1, I42.1, N11.1, J05.0, G47.33, J44.9, N13.8
Drugs: td-4208, tiotropium
SMILES: CN(CCN1CCC(CC1)OC(=O)NC1=CC=CC=C1C1=CC=CC=C1)C(=O)C1=CC=C(CN2CCC(CC2)C(N)=O)C=C1, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1
Eligibility criteria:

        Inclusion Criteria:

          -  Subject is a male or female subject 40 years of age or older

        Exclusion Criteria:

          -  Females who are pregnant, lactating, breast-feeding or planning to become pregnant
             during the study
Clinical trial NCT02521662 (phase 3, status: completed)
Conditions: smoking cessation
ICD codes: Y36.881S, Y36.891S, Y36.880S, Y36.881A, Y36.881D, Y36.890S, Y36.891A
Drugs: nicotine patch, nicotine
SMILES: CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1, CC(=O)NC1=CC=C(O)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Smoke and want to quit in the next three months

          -  Reside in New Zealand

          -  At least 18 years of age

          -  Able to provide verbal consent

          -  Have access to telephone (mobile and/or landline)

          -  Are prepared to use a nicotine patch or a nicotine patch and e-cigarette together.

          -  Only one person per household is eligible.

        Exclusion Criteria:

          -  Pregnant women

          -  Women who are breastfeeding

          -  Current users of NRT products

          -  People currently enrolled in another smoking cessation programme or other cessation
             study

          -  People who have used an e-cigarette for more than one week in the last year for
             smoking cessation

          -  Current users of non-nicotine based cessation therapies (e.g. buproprion, clonidine,
             nortriptyline or varenicline).

          -  People who have had a heart attack, stroke or severe angina within the previous two
             weeks.

          -  People who self-report a history of severe allergies and/or poorly controlled asthma.